科伦博泰生物(06990.HK) 公布，将在于2月13日至2月15日于美国圣弗朗西斯科举行的2025年美国临床肿瘤学会(ASCO)泌尿生殖系统(GU)癌症研讨会上，公布其抗人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT，前称SKB264/MK-2870)(佳泰莱)单药治疗既往接受过抗癌疗法时或治疗后病情进展的不可切除、局部晚期或转移性尿路上皮癌(UC)患者的1/2期KL264-01/MK-2870-001研究(NCT04152499)的疗效及安全性结果。
该些研究结果将于当地时间2月14日的壁报环节(摘要#796)上公布。上述研究的摘要亦将于当地时间2月10日发布在2025年ASCO GU癌症研讨会的官方网站上。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-10 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.